Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development

Journal of Pharmacological and Toxicological Methods

Volumn 70, Issue 1, 2014, Pages 73-85

  Caruso, Antonello ^a   Frances, Nicolas ^a   Meille, Christophe ^a   Greiter Wilke, Andrea ^a   Hillebrecht, Alexander ^a   Lavé, Thierry ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Cardiovascular safety pharmacology; Nonlinear mixed effects modeling; PK PD modeling; Telemetry studies; Translation to human

Indexed keywords

DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; DRUG BLOOD LEVEL; DRUG DEVELOPMENT; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; MALE; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; QT PROLONGATION; ANIMAL; DOG; DRUG EFFECTS; DRUG SCREENING; HEART RATE; LONG QT SYNDROME; MACACA FASCICULARIS; METABOLISM; PROCEDURES; SAFETY; TELEMETRY; THEORETICAL MODEL; TRANSLATIONAL RESEARCH;

ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; DOGS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; FEMALE; HEART RATE; HUMANS; LONG QT SYNDROME; MACACA FASCICULARIS; MALE; MODELS, THEORETICAL; PHARMACEUTICAL PREPARATIONS; SAFETY MANAGEMENT; TELEMETRY; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84902475474     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2014.05.004     Document Type: Article

References (78)

1. The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. International Conference on Harmonisation (ICH) Harmonised Tripartite Guidelines ICH-S7B 2005, CDER.
2. GastroPlusTM 6.1 User Manual 2009, Simulations Plus Inc., Lancaster (CA).
3. Authier S., Pugsley M.K., Troncy E., Curtis M.J. Arrhythmogenic liability screening in cardiovascular safety pharmacology: commonality between non-clinical safety pharmacology and clinical thorough QT (TQT) studies. Journal of Pharmacological and Toxicological Methods 2010, Sep-Oct, 62(2):83-88.
4. Barter P.J., Caulfield M., Eriksson M., Grundy S.M., Kastelein J.J., Komajda M., et al. Effects of torcetrapib in patients at high risk for coronary events. The New England Journal of Medicine 2007, Nov 22, 357(21):2109-2122.
5. Bazett H.C. An analysis of the time-relations of electrocardiograms. Heart 1920, 7:353-370.
6. Brown A.M. Drugs, hERG and sudden death. Cell Calcium 2004, Jun, 35(6):543-547.
7. Champeroux P., Martel E., Fowler J.S., Maurin A., Sola M.L., Jude S., et al. Calculation of QT shift in non clinical safety pharmacology studies. Journal of Pharmacological and Toxicological Methods 2009, Mar-Apr, 59(2):73-85.
8. Chan P.L., Jacqmin P., Lavielle M., McFadyen L., Weatherley B. The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects. Journal of Pharmacokinetics and Pharmacodynamics 2011, Feb, 38(1):41-61.
9. Chaves A.A., Keller W.J., O'Sullivan S., Williams M.A., Fitzgerald L.E., McPherson H.E., et al. Cardiovascular monkey telemetry: sensitivity to detect QT interval prolongation. Journal of Pharmacological and Toxicological Methods 2006, Sep-Oct, 54(2):150-158.
10. Chelly J.E., Hill D.C., Abernethy D.R., Dlewati A., Doursout M.F., Merin R.G. Pharmacodynamic and pharmacokinetic interactions between lidocaine and verapamil. Journal of Pharmacology and Experimental Therapeutics 1987, Oct, 243(1):211-216.
11. Cools F., Dhuyvetter D., Vanlommel A., Janssens S., Borghys H., Geys H., et al. A translational assessment of preclinical versus clinical tools for the measurement of cardiac contractility: comparison of LV dP/dt with echocardiography in telemetry implanted beagle dogs. Journal of Pharmacological and Toxicological Methods 2013, Oct 16, 69(1):17-23.
12. Crump K.S. A new method for determining allowable daily intakes. Fundamental and Applied Toxicology 1984, Oct, 4(5):854-871.
13. Danhof M., de Lange E.C., Della Pasqua O.E., Ploeger B.A., Voskuyl R.A. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends in Pharmacological Sciences 2008, Apr, 29(4):186-191.
14. Darpo B., Nebout T., Sager P.T. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline. Journal of Clinical Pharmacology 2006, May, 46(5):498-507.
15. Dayneka N.L., Garg V., Jusko W.J. Comparison of four basic models of indirect pharmacodynamic responses. Journal of Pharmacokinetics and Biopharmaceutics 1993, Aug, 21(4):457-478.
16. De Ponti F., Poluzzi E., Montanaro N. Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus. European Journal of Clinical Pharmacology 2001, Jun, 57(3):185-209.
17. Desai A.D., Yaw T.S., Yamazaki T., Kaykha A., Chun S., Froelicher V.F. Prognostic significance of quantitative QRS duration. The American Journal of Medicine 2006, Jul, 119(7):600-606.
18. Dorato M.A., Engelhardt J.A. The no-observed-adverse-effect-level in drug safety evaluations: use, issues, and definition(s). Regulatory Toxicology and Pharmacology: RTP 2005, Aug, 42(3):265-274.
19. Dubois V.F.S., Chain A., van der Graaf P., Leishman D., Gallacher D., McMahon N., et al. Population Approach Group in Europe (PAGE) meeting 2011, (Abstr 2226).
20. Dutta S., Matsumoto Y., Ebling W.F. Is it possible to estimate the parameters of the sigmoid Emax model with truncated data typical of clinical studies?. Journal of Pharmaceutical Sciences 1996, Feb, 85(2):232-239.
21. Erdemli G., Kim A.M., Ju H., Springer C., Penland R.C., Hoffmann P.K. Cardiac safety implications of hNav1.5 blockade and a framework for pre-clinical evaluation. Frontiers in Pharmacology 2012, 3:6.
22. Fermini B., Fossa A.A. The impact of drug-induced QT interval prolongation on drug discovery and development. Nature Reviews Drug Discovery 2003, Jun, 2(6):439-447.
23. Ferri N., Siegl P., Corsini A., Herrmann J., Lerman A., Benghozi R. Drug attrition during pre-clinical and clinical development: understanding and managing drug-induced cardiotoxicity. Pharmacology & Therapeutics 2013, Jun, 138(3):470-484.
24. Fleury A., Lave T., Jonsson F., Schmitt M., Hirkaler G., Polonchuk L., et al. A pharmacokinetic-pharmacodynamic model for cardiovascular safety assessment of R1551. Journal of Pharmacological and Toxicological Methods 2011 Jan-Feb, 63(1):123-133.
25. Frances N., Meille C., Caruso A., Fretland J., Harrison A.C., Greiter-Wilke A., Sanders M., et al. A translational threshold model to assess exposure-driven QTc changes 2012, (PAGE, Abstract 2577).
26. Fridericia L.S. The duration of systole in the electrocardiogram of normal subjects and of patients with heart disease. Acta Medica Scandinavica 1920, 53:469-486.
27. Gauer O.H. Kreislauf des blutes. Lehrbuch der Physiologie des Menschen 1960, 95-135. Urban and Schwarzenberg, München and Berlin. L. Landois, H.-U. Rosemann (Eds.).
28. Gintant G.A., Gallacher D.J., Pugsley M.K. The 'overly-sensitive' heart: sodium channel block and QRS interval prolongation. British Journal of Pharmacology 2011, Sep, 164(2):254-259.
29. Giorgi M.A., Bolanos R., Gonzalez C.D., Di Girolamo G. QT interval prolongation: preclinical and clinical testing arrhythmogenesis in drugs and regulatory implications. Current Drug Safety 2010, Jan, 5(1):54-57.
30. Guth B.D., Bass A.S., Briscoe R., Chivers S., Markert M., Siegl P.K., et al. Comparison of electrocardiographic analysis for risk of QT interval prolongation using safety pharmacology and toxicological studies. Journal of Pharmacological and Toxicological Methods 2009, Sep-Oct, 60(2):107-116.
31. Hall J.E. Guyton and Hall textbook of medical physiology 2010, Saunders, Philadelphia. 12th ed.
32. Hao K., Chen Y.C., Cao Y.G., Yu D., Liu X.Q., Wang G.J. Pharmacokinetic-pharmacodynamic modeling of telmisartan using an indirect response model in spontaneously hypertensive rats. Acta Pharmacologica Sinica 2007, May, 28(5):738-743.
33. Holzgrefe H.H., Cavero I., Buchanan L.V., Gill M.W., Durham S.K. Application of a probabilistic method for the determination of drug-induced QT prolongation in telemetered cynomolgus monkeys: effects of moxifloxacin. Journal of Pharmacological and Toxicological Methods 2007, May-Jun, 55(3):227-237.
34. Holzgrefe H.H., Cavero I., Gleason C.R., Warner W.A., Buchanan L.V., Gill M.W., et al. Novel probabilistic method for precisely correcting the QT interval for heart rate in telemetered dogs and cynomolgus monkeys. Journal of Pharmacological and Toxicological Methods 2007, Mar-Apr, 55(2):159-175.
35. Holzgrefe H., Ferber G., Champeroux P., Gill M., Honda M., Greiter-Wilke A., et al. Preclinical QT safety assessment: cross-species comparisons and human translation from an industry consortium. Journal of Pharmacological and Toxicological Methods 2014, Jan-Feb, 69(1):61-101.
36. Jones H.M., Parrott N., Jorga K., Lave T. A novel strategy for physiologically based predictions of human pharmacokinetics. Clinical Pharmacokinetics 2006, 45(5):511-542.
37. Jonker D.M., Kenna L.A., Leishman D., Wallis R., Milligan P.A., Jonsson E.N. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data. Clinical Pharmacology and Therapeutics 2005, Jun, 77(6):572-582.
38. Kao L.W., Furbee R.B. Drug-induced Q-T prolongation. The Medical Clinics of North America 2005, Nov, 89(6):1125-1144.
39. Kashani A., Barold S.S. Significance of QRS complex duration in patients with heart failure. Journal of the American College of Cardiology 2005 Dec 20, 46(12):2183-2192.
40. Keizer R.J., Gupta A., Mac Gillavry M.R., Jansen M., Wanders J., Beijnen J.H., et al. A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080. Journal of Pharmacokinetics and Pharmacodynamics 2010, Aug, 37(4):347-363.
41. Kintscher U. Reuptake inhibitors of dopamine, noradrenaline, and serotonin. Handbook of Experimental Pharmacology 2012, 209:339-347.
42. Kola I., Landis J. Can the pharmaceutical industry reduce attrition rates?. Nature Reviews Drug Discovery 2004, Aug, 3(8):711-715.
43. Langdon G., Davis J.D., McFadyen L.M., Dewhurst M., Brunton N.S., Rawal J.K., et al. Translational pharmacokinetic-pharmacodynamic modelling; application to cardiovascular safety data for PF-00821385, a novel HIV agent. British Journal of Clinical Pharmacology 2010, Apr, 69(4):336-345.
44. Langdon G., Davis J.D., McFadyen L.M., Dewhurst M., Brunton N.S., Rawal J.K., et al. Translational pharmacokinetic-pharmacodynamic modelling; application to cardiovascular safety data for PF-00821385, a novel HIV agent. British Journal of Clinical Pharmacology 2010, Apr, 69(4):336-345.
45. Laverty H., Benson C., Cartwright E., Cross M., Garland C., Hammond T., et al. How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?. British Journal of Pharmacology 2011, Jun, 163(4):675-693.
46. Leisenring W., Ryan L. Statistical properties of the NOAEL. Regulatory Toxicology and Pharmacology: RTP 1992, Apr, 15(2 Pt 1):161-171.
47. Lentner C. Geigy scientific tables: Heart and circulation 1990, Ciba-Geigy Limited. 8th ed. C. Lentner (Ed.).
48. Lovell D.P. Dose-response and threshold-mediated mechanisms in mutagenesis: Statistical models and study design. Mutation Research 2000, Jan 3, 464(1):87-95.
49. Lund L.H., Jurga J., Edner M., Benson L., Dahlstrom U., Linde C., et al. Prevalence, correlates, and prognostic significance of QRS prolongation in heart failure with reduced and preserved ejection fraction. European Heart Journal 2013 Feb, 34(7):529-539.
50. Lutz W.K., Lutz R.W. Statistical model to estimate a threshold dose and its confidence limits for the analysis of sublinear dose-response relationships, exemplified for mutagenicity data. Mutation Research 2009, Aug, 678(2):118-122.
51. Lynch A., Harvey J., Aylott M., Nicholas E., Burman M., Siddiqui A., et al. Investigations into the concept of a threshold for topoisomerase inhibitor-induced clastogenicity. Mutagenesis 2003, Jul, 18(4):345-353.
52. Madias J.E. Drug-induced QRS, morphology and duration changes. Cardiology Journal 2008, 15(6):505-509.
53. Mager D.E., Jusko W.J. Development of translational pharmacokinetic-pharmacodynamic models. Clinical Pharmacology and Therapeutics 2008, Jun, 83(6):909-912.
54. Mager D.E., Wyska E., Jusko W.J. Diversity of mechanism-based pharmacodynamic models. Drug metabolism and disposition: The biological fate of chemicals 2003, May, 31(5):510-518.
55. Markert M., Klumpp A., Trautmann T., Mayer K., Stubhan M., Guth B. The value added by measuring myocardial contractility 'in vivo' in safety pharmacological profiling of drug candidates. Journal of Pharmacological and Toxicological Methods 2007, Sep-Oct, 56(2):203-211.
56. MATLAB High-performance numeric computation and visualization software, R 2009, The Math Works, Natick MA.
57. Munos B. Lessons from 60years of pharmaceutical innovation. Nature Reviews Drug Discovery 2009, Dec, 8(12):959-968.
58. Nolan E.R., Feng M.R., Koup J.R., Liu J., Turluck D., Zhang Y., et al. A novel predictive pharmacokinetic/pharmacodynamic model of repolarization prolongation derived from the effects of terfenadine, cisapride and E-4031 in the conscious chronic av node-ablated, His bundle-paced dog. Journal of Pharmacological and Toxicological Methods 2006, Jan-Feb, 53(1):1-10.
59. Ollerstam A., Visser S.A., Duker G., Forsberg T., Persson A.H., Nilsson L.B., et al. Comparison of the QT interval response during sinus and paced rhythm in conscious and anesthetized beagle dogs. Journal of Pharmacological and Toxicological Methods 2007, Sep-Oct, 56(2):131-144.
60. Ollerstam A., Visser S.A., Persson A.H., Eklund G., Nilsson L.B., Forsberg T., et al. Pharmacokinetic-pharmacodynamic modeling of drug-induced effect on the QT interval in conscious telemetered dogs. Journal of Pharmacological and Toxicological Methods 2006, Mar-Apr, 53(2):174-183.
61. Parkinson J., Visser S.A., Jarvis P., Pollard C., Valentin J.P., Yates J.W., et al. Translational pharmacokinetic-pharmacodynamic modeling of QTc effects in dog and human. Journal of Pharmacological and Toxicological Methods 2013, Apr 6.
62. Paul L., Hastie C.E., Li W.S., Harrow C., Muir S., Connell J.M., et al. Resting heart rate pattern during follow-up and mortality in hypertensive patients. Hypertension 2010, Feb, 55(2):567-574.
63. Persky A.M., Berry N.S., Pollack G.M., Brouwer K.L. Modelling the cardiovascular effects of ephedrine. British Journal of Clinical Pharmacology 2004, May, 57(5):552-562.
64. Peters R.W., Byington R.P., Barker A., Yusuf S. Prognostic value of prolonged ventricular repolarization following myocardial infarction: the BHAT experience. The BHAT Study Group. Journal of Clinical Epidemiology 1990, 43(2):167-172.
65. Piotrovsky V. Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation. The AAPS Journal 2005, 7(3):E609-E624.
66. Pugsley M.K., Authier S., Curtis M.J. Principles of safety pharmacology. British Journal of Pharmacology 2008, Aug, 154(7):1382-1399.
67. Purchase I.F., Auton T.R. Thresholds in chemical carcinogenesis. Regulatory Toxicology and Pharmacology: RTP 1995, Dec, 22(3):199-205.
68. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovascular Research 2003, Apr 1, 58(1):32-45.
69. Redfern W.S., Ewart L., Hammond T.G., Bialecki R., Kinter L., Lindgren S., et al. Impact and frequency of different toxicities throughout the pharmaceutical life cycle. The Toxicologist 2010, 114:1081.
70. Roden D.M. Drug-induced prolongation of the QT interval. The New England Journal of Medicine 2004, Mar 4, 350(10):1013-1022.
71. Safety pharmacology studies for human pharmaceuticals. International Conference on Harmonisation (ICH) Harmonised Tripartite Guidelines ICH-S7A 2001, CDER.
72. Sagie A., Larson M.G., Goldberg R.J., Bengtson J.R., Levy D. An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). The American Journal of Cardiology 1992, Sep 15, 70(7):797-801.
73. Sheiner L.B., Rosenberg B., Melmon K.L. Modelling of individual pharmacokinetics for computer-aided drug dosage. Computers and Biomedical Research, an International Journal 1972, Oct, 5(5):411-459.
74. Snelder N., Ploeger B.A., Luttringer O., Rigel D.F., Webb R.L., Feldman D., et al. PKPD modelling of the interrelationship between mean arterial BP, cardiac output and total peripheral resistance in conscious rats. British Journal of Pharmacology 2013, Aug, 169(7):1510-1524.
75. Stroh M., Addy C., Wu Y., Stoch S.A., Pourkavoos N., Groff M., et al. Model-based decision making in early clinical development: Minimizing the impact of a blood pressure adverse event. The AAPS Journal 2009, Mar, 11(1):99-108.
76. Watson K.J., Gorczyca W.P., Umland J., Zhang Y., Chen X., Sun S.Z., et al. Pharmacokinetic-pharmacodynamic modelling of the effect of moxifloxacin on QTc prolongation in telemetered cynomolgus monkeys. Journal of Pharmacological and Toxicological Methods 2011, May-Jun, 63(3):304-313.
77. Wezler K., Böger A. Die Dynamik des arteriellen systems. Ergebnisse der Physiologie München 1939, 292-606. Verlag von JF Bergmann. L. Asher, K. Sapiro (Eds.).
78. Yanagimoto T., Yamamoto E. Estimation of safe doses: Critical review of the hockey stick regression method. Environmental Health Perspectives 1979, Oct, 32:193-199.